Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AVNR dual catalyst phase 2 (nuedexta) results 3rd qtr and PDUFA avp-825 Migraine 11-26-14 http://stockcharts.com/h-sc/ui?s=AVNR
links
http://seekingalpha.com/article/2194323-avanir-pharmaceuticals-shares-could-have-significant-upside-ahead
NPSP might be spoken for by then: #msg-102751318 :- )
(Disclosure: No position)
KERX PDUFA 9-7-14 http://stockcharts.com/h-sc/ui?s=KERX
AEZS PDUFA 11-5 http://stockcharts.com/h-sc/ui?s=AEZS
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=101482458&txt2find=aezs
took small starter in this yesterday at 1.07. Sold out a few months ago got in way to early. Still early and chance of dilution but as tradetomuch points out this could run easily.
Agree. And I have as well.
Great board...bookmarked
ANAC 7-29 PDUFA (14.71) http://stockcharts.com/h-sc/ui?s=ANAC
ACRX PDUFA 7-27 (9.16) http://stockcharts.com/h-sc/ui?s=acrx
HALO ADCOM 7-31 (7.96) http://stockcharts.com/h-sc/ui?s=halo
SPPI PDUFA 8-9 (7.41) http://stockcharts.com/h-sc/ui?s=SPPI
MACK ( 7.52 ) phase 2 data breast cancer drug end
http://stockcharts.com/h-sc/ui?s=mack
XOMA (4.05) phase 3 news June or July??
http://stockcharts.com/h-sc/ui?s=xoma
ANTH(2.98) phase 3 update due mid 2014
http://stockcharts.com/h-sc/ui?s=anth
ACST (.87) phase 2 results by end of 2nd qtr
http://stockcharts.com/h-sc/ui?s=acst
EGRX 7-6 PDUFA watch for $heff to start a position soon. Looking to get in this week possibly.
HRTX late june/early July resubmission of nda after CRL last year under old ticker. Has uplisted and changed ticker/brought in some new key management. Had some issues with manufacturer I believe that delayed their response to Crl. Had a r/s to get uplisted. AT or about R/s levels now.
Insv after getting vote for r.s out of way this should move in late summer leading up to nda
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTQxMDAxfENoaWxkSUQ9MjMxMDE2fFR5cGU9MQ==&t=1
Great idea for a board.
BiotechnologyEvents.com
Aezs added yesterday at 1.23. Hard to tell how much this can run if the company dilutes heavily on the run up.
.TRLPF .72 PDUFA date in May. hoping this moves like other Canadian stock NRIFF did leading up to approval.
Trlpf Pdufa
Market Wire
— 7:55 AM ET 01/17/2014
TORONTO, ONTARIO -- (Marketwired) -- 01/17/14 -- Trimel Pharmaceuticals Corporation (TRLPF) today announced that the United States Food and Drug Administration ("FDA") has decided to extend the Prescription Drug User Fee Act (PDUFA) target action date for the CompleoTRT™ new drug application ("NDA") from February 28, 2014 to May 28, 2014. This will provide the FDA with the required time for a full review of the submission in light of the previously announced decision by the Company to amend its proposed label.
"As the FDA considered the change in labelling a major amendment, we understand that this extension is consistent with their normal practices in these circumstances," stated Tom Rossi, President and Chief Executive Officer. "We will continue to work closely with the FDA in order to obtain approval for this important therapy as quickly as possible."
About CompleoTRT™
Trimel's most advanced product candidate, CompleoTRT™, is a bioadhesive intranasal gel formulation of testosterone. CompleoTRT™ is designed with a view to providing hypogonadal patients with superior safety and enhanced convenience over currently available treatment options.
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.
Notice regarding forward-looking statements:
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the Company is subject to a number of risks and uncertainties, including that CompleoTRT™ may not be approved by the FDA or that any approval may be delayed, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our prospectus dated April 18, 2013 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |